270 Results for "

Checkpoint

" in MedChemExpress (MCE) Product Catalog:
Products (270)

270 Results for "Checkpoint" in MCE Product Catalog:

6
6 Cited Publications
Cat. No.: HY-17493A
CAS No.: 1303609-37-1
Target:  

MDM-2/p53 Apoptosis

Research Areas:  

Neurological Disease Cancer

MI-773 TFA is an orally active, selective MDM2-p53 interaction inhibitor with a Ki of 0.88 nM for MDM2. MI-773 TFA blocks the MDM2-TP53 interaction. MI-773 TFA potently activates p53. MI-773 TFA induces Apoptosis. MI-773 TFA causes tumor regression in xenograft models of adenoid cystic carcinoma. MI-773 TFA exhibits anticancer effects in neuroblastoma. MI-773 TFA can be used for the research of adenoid cystic carcinoma .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-18175
CAS No.: 1404095-34-6
Research Areas:  

Cancer

CCT244747 is a potent, orally bioavailable and highly selective CHK1 inhibitor, with an IC50 of 7.7 nM; CCT244747 also abrogates G2 checkpoint with an IC50 of 29 nM.
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-107407
CAS No.: 135897-06-2
Purity:  98.30%
Research Areas:  

Cancer

SB-218078 is a potent, selective, ATP-competitive and cell-permeable checkpoint kinase 1 (Chk1) inhibitor that inhibits Chk1 phosphorylation of cdc25C with an IC50 of 15 nM. SB-218078 is less potently inhibits Cdc2 (IC50 of 250 nM) and PKC (IC50 of 1000 nM). SB-218078 causes apoptosis by DNA damage and cell cycle arrest .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-156677
CAS No.: 2648257-56-9
Purity:  99.90%
Target:  

METTL3

Research Areas:  

Cancer

STC-15 is an orally active RNA methyltransferase METTL3 inhibitor with the activity of activating anti-tumor immunity and reshaping the tumor microenvironment. STC-15 inhibits tumor growth by activating anti-cancer immune responses associated with increased interferon signaling and synergizes with T-cell checkpoint blockade. STC-15 can be used in the study of proliferative diseases such as cancer and autoimmune diseases .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P80799
Synonyms: CHEK2; CDS1; CHK2; RAD53; Serine/threonine-protein kinase Chk2; CHK2 Checkpoint homolog; Cds1 homolog; Hucds1; hCds1; Checkpoint kinase 2

Host:  

Rabbit

Application:  

WB, ICC/IF, IHC-P

Reactivity:  

Human, Mouse, Rat

loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-112162
CAS No.: 1578245-44-9
Purity:  98.65%
Target:  

Mps1

Research Areas:  

Cancer

BOS-172722 is an inhibitor of monopolar spindle 1 (MPS1) checkpoint with an IC50 of 11 nM and 63 nM for MPS1 (1 mM ATP) and P-MPS1, respectively. BOS-172722 also has potential for the study of various forms of breast cancer .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P99051
CAS No.: 2226224-30-0
Synonyms: BAY 1834942
Tinurilimab (Bay 1834942) is an anti-CEACAM6 (carcinoembryonic antigen-related cell adhesion molecule 6) humanized IgG2 monoclonal antibody. CEACAM6 is an immune checkpoint regulator suppressing the activity of effector T-cells against tumors. Tinurilimab shows an increased tumor cell killing effect in the tumor-cell/T-cell co-culture system .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-132832
CAS No.: 2079939-05-0
Purity:  99.13%
Synonyms: DRP-104
Target:  

Drug Intermediate

Research Areas:  

Cancer

Sirpiglenastat (DRP-104) is a broad acting glutamine antagonist. Sirpiglenastat has anticancer effects by directly targeting tumor metabolism and simultaneously inducing a potent antitumor immune response .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-101093
CAS No.: 1673534-76-3
Purity:  99.39%
Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology Cancer

CA-170 is an orally delivered dual inhibitor of VISTA and PD-L1. CA-170 exhibits potent rescue of proliferation and effector functions of T cells inhibited by PD-L1/L2 and VISTA with selectivity over other immune checkpoint proteins as well as a broad panel of receptors and enzymes .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P80082
Synonyms: CHK1, CHEK1, Serine/threonine-protein kinase Chk1, CHK1 Checkpoint homolog, Cell cycle Checkpoint kinase, Checkpoint kinase-1

Host:  

Rabbit

Application:  

WB, ICC/IF, IHC-P, FC

Reactivity:  

Human, Mouse

loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-135960
CAS No.: 2408648-20-2
Purity:  99.63%
Target:  

FGFR Apoptosis

Research Areas:  

Cancer

BO-264 is a highly potent and orally active transforming acidic coiled-coil 3 (TACC3) inhibitor with an IC50 of 188 nM and a Kd of 1.5 nM. BO-264 specifically blocks the function of FGFR3-TACC3 fusion protein. BO-264 induces spindle assembly checkpoint (SAC)-dependent mitotic arrest, DNA damage and apoptosis. BO-264 has broad-spectrum antitumor activity .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-100591
CAS No.: 709002-46-0
Purity:  ≥99.0%
SirReal2 is a potent, isotype-selective Sirt2 inhibitor with an IC50 value of 140 nM and has very little effect on the activities of Sirt3-5. SirReal2 leads to tubulin hyperacetylation in HeLa cells and induces destabilization of the checkpoint protein BubR1. SirReal2 combined with VS-5584 (HY-16585) suppresses tumor growth and extends the survival rate of mice in tumor xenograft model. SirReal2 is is promising for research of cancer, inflammation and neurodegeneration .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99777
CAS No.: 2131089-46-6
Synonyms: TTI-621

Target:  

CD47

Research Areas:  

Cancer

Ontorpacept (TTI-621) is a soluble fusion protein that consists of the human SIRPα N-terminal (1-118) linked to the Fc region of human IgG1. The N-terminal (1-118)-fragment of ontorpacept is a binding domain for CD47 which is an inhibitor of phagocytosis by macrophages. Ontorpacept is a CD47-blocking checkpoint inhibitor with antitumor activity .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-131446
CAS No.: 2120398-39-0
Research Areas:  

Cancer

Chk1-IN-5 is a potent checkpoint kinase 1 (Chk1) inhibitor. Chk1-IN-5 inhibits Chk1 phosphorylation and inhibits tumor growth in colon cancer xenograft model .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P80455
Synonyms: CHK1, CHEK1, Serine/threonine-protein kinase Chk1, CHK1 Checkpoint homolog, Cell cycle Checkpoint kinase, Checkpoint kinase-1

Host:  

Rabbit

Application:  

WB, IHC-P

Reactivity:  

Human

loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P80083
Synonyms: CDS1, CHK2, RAD53, CHEK2, Serine/threonine-protein kinase Chk2, CHK2 Checkpoint homolog, Cds1 homolog, Checkpoint kinase 2, Hucds1, hCds1

Host:  

Rabbit

Application:  

WB, ICC/IF, IHC-P, IP

Reactivity:  

Human

loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-145034
CAS No.: 2600559-12-2
Purity:  98.39%
Target:  

Kinesin

Research Areas:  

Cancer

KIF18A-IN-1 is an inhibitor of the mitotic kinesin KIF18A with anti-tumor activity. KIF18A targeted inhibitors may activate mitotic checkpoints and selectively kill chromosomally unstable cancer cells .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-13649
CAS No.: 204205-90-3
Purity:  99.89%
Synonyms: ZIO 301; D 24851
Indibulin (ZIO 301), an orally applicable inhibitor of tubulin assembly, shows potent anticancer activity with a minimal neurotoxicity. Indibulin reduces inter-kinetochoric tension, produces aberrant spindles, activates mitotic checkpoint proteins Mad2 and BubR1, and induces mitotic arrest and apoptosis .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-149874
CAS No.: 2407854-18-4
Purity:  99.31%
Target:  

DGK

Research Areas:  

Inflammation/Immunology Cancer

BMS-502 (Compound 22) is a potent dual inhibitor of diacylglycerol kinase (DGK) α and ζ with IC50 of 4.6 nM and 2.1 nM. BMS-502 enhanced T cell immune responses in mice. BMS-502 can be used in tumor immunity related research .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99144A

Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology Cancer

Anti-Mouse PD-1 Antibody (S-5001) is a selective inhibitor targeting PD-1, blocking the PD-1/PD-L1 immune checkpoint axis through competitive binding to PD-1. Anti-Mouse PD-1 Antibody (S-5001) works by reversing the tumor immunosuppressive microenvironment and reactivating the anti-tumor activity of cytotoxic T lymphocytes. It can be used in research on tumors such as melanoma and HPV-positive oropharyngeal squamous cell carcinoma. Anti-Mouse PD-1 Antibody (S-5001) is often combined with photothermal therapy, chemotherapy, etc., to enhance efficacy .
loading...
    loading...